FI924778A0 - Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning - Google Patents

Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning

Info

Publication number
FI924778A0
FI924778A0 FI924778A FI924778A FI924778A0 FI 924778 A0 FI924778 A0 FI 924778A0 FI 924778 A FI924778 A FI 924778A FI 924778 A FI924778 A FI 924778A FI 924778 A0 FI924778 A0 FI 924778A0
Authority
FI
Finland
Prior art keywords
csf
och
analyzing
fabric
action
Prior art date
Application number
FI924778A
Other languages
English (en)
Other versions
FI924778A (fi
Inventor
Glenn Pierce
Bruce W Altrock
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI924778A0 publication Critical patent/FI924778A0/fi
Publication of FI924778A publication Critical patent/FI924778A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI924778A 1991-02-22 1992-10-21 Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning FI924778A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65978091A 1991-02-22 1991-02-22
US82149892A 1992-01-21 1992-01-21
PCT/US1992/001245 WO1992014480A1 (en) 1991-02-22 1992-02-19 Use of gm-csf and g-csf to promote accelerated wound healing

Publications (2)

Publication Number Publication Date
FI924778A0 true FI924778A0 (fi) 1992-10-21
FI924778A FI924778A (fi) 1992-10-21

Family

ID=27097898

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924778A FI924778A (fi) 1991-02-22 1992-10-21 Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning

Country Status (11)

Country Link
US (1) US6689351B1 (fi)
EP (1) EP0526630A4 (fi)
JP (1) JPH05506673A (fi)
AU (1) AU1462392A (fi)
CA (1) CA2081104A1 (fi)
FI (1) FI924778A (fi)
IE (1) IE920560A1 (fi)
IL (1) IL101028A0 (fi)
NO (1) NO924073D0 (fi)
PT (1) PT100152A (fi)
WO (1) WO1992014480A1 (fi)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
WO1994021276A1 (en) * 1993-03-17 1994-09-29 Otsuka Pharmaceutical Co., Ltd. Agent for preventing and treating digestive mucosal disorders
RU2146148C1 (ru) * 1993-03-26 2000-03-10 Амген Инк. Терапевтическое применение фактора роста кератиноцитов (фрк)
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US5578566A (en) * 1993-05-04 1996-11-26 The United States Of America As Represented By The Department Of Health And Human Services KGF receptor-derived antagonists of KGF binding
US5599788A (en) * 1994-07-01 1997-02-04 Advanced Tissue Sciences Method for accelerating skin wound healing with H3 protein
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
AU747598B2 (en) * 1995-08-18 2002-05-16 Renovo Limited Pharmaceutical composition containing stimulators of interferon-gamma
IT1276213B1 (it) * 1995-10-06 1997-10-27 Mendes Srl Composizioni dermatologiche e cosmetiche atte all'applicazione topica, ad effetto modulante sulle ceramidi endogene dell'epidermide
PT1486565E (pt) * 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
DE69821011T3 (de) 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
EP1041996A4 (en) 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US7745488B2 (en) * 2001-04-18 2010-06-29 Prometic Biosciences, Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
WO2003035102A1 (en) * 2001-10-26 2003-05-01 University Technologies International, Inc. Use of egf to inhibit pathogenic infections of the urogenital tract
DE10154579A1 (de) * 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
EP1459759A4 (en) * 2001-11-19 2007-08-29 Kyowa Hakko Kogyo Kk MEDICAMENT FOR THE MOBILIZATION OF PLURIPOTENTIAL STEM CELLS FROM TISSUE IN THE PERIPHERAL BLOOD
FR2834899B1 (fr) * 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique des facteurs g-csf, gm-csf et scf
US7048914B2 (en) 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7374754B2 (en) 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
KR20070006668A (ko) * 2003-10-14 2007-01-11 추가이 세이야쿠 가부시키가이샤 신장 질환 치료제
CA2543817C (en) 2003-10-27 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Fibroblast-mobilization agent containing a g-csf for repair of myocardial infarct lesion
SE0400942D0 (sv) * 2004-04-08 2004-04-08 Henrik Arnberg Composition and method
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
AU2005275108B2 (en) * 2004-07-16 2011-05-12 Nektar Therapeutics Conjugates of a GM-CSF moiety and a polymer
CA2584553A1 (en) * 2004-09-17 2006-03-23 Cellgentech, Inc. External agent for treatment of skin ulcer
JP2006137747A (ja) * 2004-10-14 2006-06-01 Hayashibara Biochem Lab Inc サイトカイン類及び／又はケモカイン類産生増強剤
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
CA2617064A1 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
WO2007075199A1 (en) 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
US20100137190A1 (en) * 2006-03-22 2010-06-03 Cellgentech, Inc. Liquid composition for external application and preparation for external application for treatment of skin ulcer
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
EP2139447A2 (en) * 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
US20120121547A1 (en) * 2010-09-16 2012-05-17 Wagner Donald J Methods and compositions for treating chronic wounds
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
EP3104874B1 (en) * 2014-02-05 2020-01-01 Reponex Pharmaceuticals A/S Compositions to promote the healing of skin ulcers and wounds
WO2015177379A2 (en) * 2014-05-23 2015-11-26 Reponex Pharmaceuticals Aps Compositions for promoting the healing of wounds
EP3848047A1 (en) 2014-07-24 2021-07-14 Reponex Pharmaceuticals APS Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
US9820953B2 (en) 2016-02-26 2017-11-21 Omni Bioceutical Innovations, Inc. Compositions of bioactive fulvate fractions and uses thereof
EP3639021A4 (en) * 2017-06-14 2021-06-09 McMaster University WOUND HEALING BIOMARKERS
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5110604A (en) * 1988-06-30 1992-05-05 Collagen Corporation Processes for producing collagen matrixes and methods of using same
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
WO1990008554A1 (en) * 1989-01-30 1990-08-09 Schering Corporation Treatment of leukocyte dysfunction with gm-csf
EP0463037A1 (en) * 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor

Also Published As

Publication number Publication date
JPH05506673A (ja) 1993-09-30
PT100152A (pt) 1993-05-31
US6689351B1 (en) 2004-02-10
EP0526630A4 (en) 1993-08-11
IL101028A0 (en) 1992-11-15
EP0526630A1 (en) 1993-02-10
AU1462392A (en) 1992-09-15
IE920560A1 (en) 1992-08-26
WO1992014480A1 (en) 1992-09-03
CA2081104A1 (en) 1992-08-23
FI924778A (fi) 1992-10-21
NO924073L (no) 1992-10-21
NO924073D0 (no) 1992-10-21

Similar Documents

Publication Publication Date Title
FI924778A0 (fi) Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning
FI923983A (fi) Kymotrypsinlika proteaser och deras inhibitorer
FI932285A (fi) Skyddshjaelm och loestagbart ansiktsskydd
FI934195A0 (fi) Kompoundkromkatalysatorer och polymerisationer under anvaendning av dessa
FI923701A (fi) Foerfarande foer saendning och mottagning av mottagarspecifierade program
FI88744B (fi) Foerfarande och anordning foer reglering av bergborrning
FI920396A (fi) Foerfarande foer reglering av en reaktiv sputteringsprocess och anordning foer utfoerande av foerfarandet
FI925480A (fi) Vattenloeslig pentacyklisk triterpenkomposition och foerfarande foer framstaellning av densamma
FI922822A (fi) Lindningsanordning och foerfarande foer lindning av en materialrulle
FI922098A (fi) Termisk krackningsugn och process
FI88433B (fi) Anordning foer ingaongs- och utgaongsluft och luftkonditioneringsfoerfarande
FI921284A (fi) Framstaellnin av styva skum och komposition anvaendbar daeri
FI931628A (fi) Identifieringsanordning och foerfarande foer saekerhetssystem
FI931869A0 (fi) Finishingmedel foer yta och foerfarande foer deras framstaellning
FI921575A (fi) Foerfarande och anordning foer tillslutning av behaollare
FI932114A (fi) Maolspecifika erytrocyter och tromboerytrocyter
FI913985A (fi) Brandbegraensare och foerfarande foer laosning av tillslutningsorganet av brandbegraensaren
FI913816A (fi) Foerfarande och arrangemang foer starning av foerbraenningsmotor
FI922389A (fi) Anordning foer framstaellning av en pressmantel avsedd foer bruk i pappersindustrin och pressmantel framstaelld daermed
FI914455A (fi) Foerfarande och anordning foer behandling av loesgods
FI932805A (fi) Smoerjmedel bestaoende av en blandning av luft och olja
FI922026A (fi) Anordning foer sortering och rengoering av pappersmaterial
FI930002A (fi) Renings- och aotervinningsfoerfarande och anordning foer utfoerande av foerfarandet
FI88938B (fi) Foerfarande och anordning foer skaerpning av ytan foer traeslipsmaskinens slipsten
FI925983A0 (fi) Maenniskans meg-csf-protein och foerfaranden

Legal Events

Date Code Title Description
FD Application lapsed